Healthcare / BiotechnologyShenzhen
$48.91
-0.61 (-1.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $134.8M · quality 78.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.7B
P/E
34.9x
↑EV/EBITDA
18.6x
↑ROE
7.0%
↑Gross Margin
34.7%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.1%
FCF CAGR
-4.7%
FCF margin
11.2%
FCF / Net income
0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $851.0M · net income $136.9M · FCF $94.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $851.0M | $851.0M | $744.0M | $721.4M | $637.5M |
| Net Income | $136.9M | $136.9M | $140.2M | $162.5M | $113.4M |
| EBITDA | $193.6M | $193.6M | $197.5M | $217.7M | $164.4M |
| EPS | 1.43 | 1.43 | 1.47 | 2.08 | 1.38 |
| Gross Margin | 34.7% | 34.7% | 37.1% | 39.8% | 36.8% |
| Operating Margin | 15.9% | 15.9% | 17.5% | 20.6% | 17.6% |
| Net Margin | 16.1% | 16.1% | 18.8% | 22.5% | 17.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.05 | 0.01 | 0.01 |
| Current Ratio | 6.01 | 6.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $94.9M | $94.9M | $134.8M | $172.7M | $109.6M |
| Returns | |||||
| ROE | 7.0% | 7.0% | 7.7% | 9.3% | 7.1% |
| Valuation | |||||
| P/E | 34.94 | 34.94 | 33.40 | 28.91 | 43.94 |
| EV/EBITDA | 18.59 | 18.59 | 18.80 | 17.07 | 21.16 |
| P/B | 2.38 | 2.38 | 2.56 | 2.69 | 3.14 |
| Growth & Yield | |||||
| Revenue Growth | 14.4% | 14.4% | 3.1% | 13.2% | — |
| EPS Growth | -2.7% | -2.7% | -29.3% | 50.7% | — |
| Dividend Yield | 0.3% | 0.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
44.8%
EPS terminal req.
$4.34
Spread vs growth
-47.5%
5Y implied EPS CAGR
29.7%
EPS terminal req.
$5.25
Spread vs growth
-32.4%
10Y implied EPS CAGR
19.5%
EPS terminal req.
$8.46
Spread vs growth
-22.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.6%
Start / end P/E
29.8x → 35.1x
EPS bridge
1.47 → 1.43
Residual
-0.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.